Disappointment and California's Bubble Baby Saga: Some CIRM Directors Look to Avoid a Repetition

$43 million taxpayer investment, trial delayed, two years and counting

How to ensure the patient perspective — Kristiina Vuori, CIRM director (SBP photo)

For the first time in two years, the directors of the $12 billion California stem cell agency have discussed -- in public -- the case of the “bubble babies” and a stalled treatment that would save the children from their life-threatening affliction. 

The discussion lasted o…